Oral iron-supplementation represents the most common treatment for iron deficiency, a widely diffused mineral insufficiency. Seven commercial products containing different chelating agents (i.e. lipidic Fe (III)-pyrophosphate, Fe (III)-pyrophosphate, lipidic Fe (II)-sulphate, Fe (III)-saccharate and Fe (III)-EDTA) were analyzed. Infrared and thermal analyses highlighted that ferrous ions complexes were able to strictly interact with ascorbic acid thus forming stable soluble systems. Dynamic light scattering (DLS) analysis pointed out that lipidic Fe (II)-sulphate formulation showed the largest particle size (i.e. 184 nm against 120 nm found for lipidic Fe (III)-pyrophosphate based formulations) but showed the lowest PDI (0.25 against 0.30) that was not subjected to change after 7 days. Moreover, lipidic Fe (II)-sulphate formulation guaranteed a better bioavailability of iron using Caco-2 Cell model, permitting the absorption of more than 40% of administered iron against 20–30% found for formulations containing Fe (III) ions.

Pepi, S., Talarico, L., Leone, G., Bonechi, C., Tamasi, G., Clemente, I., et al. (2024). Effect of oxidation state and chelating agent on iron bio-accessibility from different commercial iron-supplements. JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY, 94 [10.1016/j.jddst.2024.105535].

Effect of oxidation state and chelating agent on iron bio-accessibility from different commercial iron-supplements

Pepi S.
;
Talarico L.;Leone G.
;
Bonechi C.;Tamasi G.;Clemente I.;Consumi M.;Bisozzi F.;Ietta F.;Rossi C.;Magnani A.
2024-01-01

Abstract

Oral iron-supplementation represents the most common treatment for iron deficiency, a widely diffused mineral insufficiency. Seven commercial products containing different chelating agents (i.e. lipidic Fe (III)-pyrophosphate, Fe (III)-pyrophosphate, lipidic Fe (II)-sulphate, Fe (III)-saccharate and Fe (III)-EDTA) were analyzed. Infrared and thermal analyses highlighted that ferrous ions complexes were able to strictly interact with ascorbic acid thus forming stable soluble systems. Dynamic light scattering (DLS) analysis pointed out that lipidic Fe (II)-sulphate formulation showed the largest particle size (i.e. 184 nm against 120 nm found for lipidic Fe (III)-pyrophosphate based formulations) but showed the lowest PDI (0.25 against 0.30) that was not subjected to change after 7 days. Moreover, lipidic Fe (II)-sulphate formulation guaranteed a better bioavailability of iron using Caco-2 Cell model, permitting the absorption of more than 40% of administered iron against 20–30% found for formulations containing Fe (III) ions.
2024
Pepi, S., Talarico, L., Leone, G., Bonechi, C., Tamasi, G., Clemente, I., et al. (2024). Effect of oxidation state and chelating agent on iron bio-accessibility from different commercial iron-supplements. JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY, 94 [10.1016/j.jddst.2024.105535].
File in questo prodotto:
File Dimensione Formato  
articolo_Lipo.pdf

non disponibili

Descrizione: articolo
Tipologia: PDF editoriale
Licenza: NON PUBBLICO - Accesso privato/ristretto
Dimensione 2.05 MB
Formato Adobe PDF
2.05 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11365/1257933